Sleep · 2018
The effect of zolpidem on cognitive function and postural control at high altitude.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bouzat Pierre, Séchaud Guillaume, Banco Pierre, Davranche Karen, Casini Laurence, Baillieul Sébastien, Manhes Pauline, Botrè Fancesco, Mazzarino Monica, De la Torre Xavier, Robach Paul, Verges Samuel
Аннотация
STUDY OBJECTIVES: Sleep is altered at high altitude leading many mountaineers to use hypnotics in order to improve sleep efficiency. While after a full night at altitude the short-acting hypnotic zolpidem does not appear to alter cognitive function, residual adverse effects should be considered following early waking-up as performed by mountaineers. We hypothesized that zolpidem intake at high altitude would alter cognitive function 4 hours after drug intake.
METHODS: In a randomized double-blind controlled cross-over study, 22 participants were evaluated during two nights at sea level and two nights at 3800 m, 4 hours after zolpidem (10 mg) or placebo intake at 10:00 pm. Polygraphic recording was performed until waking-up at 01:30 am. Sleep quality, sleepiness and symptoms of acute mountain sickness were assessed by questionnaires. Two cognitive tasks (Simon task and duration-production task) were performed at rest and during exercise and postural control was evaluated.
RESULTS: Zolpidem increased reaction time in all conditions (zolpidem 407 ± 9 ms vs. placebo 380 ± 11 ms; p < 0.001) and error rate in incongruent trials only (10.2 ± 1.1% vs. 7.8 ± 0.8%; p < 0.01) in the Simon task and increased time perception variability (p < 0.001). Zolpidem also altered postural parameters (e.g. center of pressure area, zolpidem 236 ± 171.5 mm2 vs. placebo 119.6 ± 59 mm2; p < 0.001). Zolpidem did not affect apnea-hypopnea index and mean arterial oxygen saturation (p > 0.05) but increased sleep quality (p < 0.001). Zolpidem increased symptoms of acute mountain sickness and sleepiness (p < 0.05).
CONCLUSIONS: Acute zolpidem intake at high altitude alters cognitive functions and postural control during early wakening which may be deleterious for safety and performances of climbers.
METHODS: In a randomized double-blind controlled cross-over study, 22 participants were evaluated during two nights at sea level and two nights at 3800 m, 4 hours after zolpidem (10 mg) or placebo intake at 10:00 pm. Polygraphic recording was performed until waking-up at 01:30 am. Sleep quality, sleepiness and symptoms of acute mountain sickness were assessed by questionnaires. Two cognitive tasks (Simon task and duration-production task) were performed at rest and during exercise and postural control was evaluated.
RESULTS: Zolpidem increased reaction time in all conditions (zolpidem 407 ± 9 ms vs. placebo 380 ± 11 ms; p < 0.001) and error rate in incongruent trials only (10.2 ± 1.1% vs. 7.8 ± 0.8%; p < 0.01) in the Simon task and increased time perception variability (p < 0.001). Zolpidem also altered postural parameters (e.g. center of pressure area, zolpidem 236 ± 171.5 mm2 vs. placebo 119.6 ± 59 mm2; p < 0.001). Zolpidem did not affect apnea-hypopnea index and mean arterial oxygen saturation (p > 0.05) but increased sleep quality (p < 0.001). Zolpidem increased symptoms of acute mountain sickness and sleepiness (p < 0.05).
CONCLUSIONS: Acute zolpidem intake at high altitude alters cognitive functions and postural control during early wakening which may be deleterious for safety and performances of climbers.